No headlines found.
Leap Therapeutics Announces $40 Million Private Placement
PRNewswire (Thu, 11-Apr 8:30 AM ET)
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
PRNewswire (Mon, 18-Mar 7:00 AM ET)
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
Leap Therapeutics trades on the NASDAQ stock market under the symbol LPTX.
As of April 24, 2024, LPTX stock price climbed to $3.29 with 193,597 million shares trading.
LPTX has a beta of 3.94, meaning it tends to be more sensitive to market movements. LPTX has a correlation of 0.14 to the broad based SPY ETF.
LPTX has a market cap of $84.22 million. This is considered a Micro Cap stock.
In the last 3 years, LPTX stock traded as high as $41.70 and as low as $1.24.
The top ETF exchange traded funds that LPTX belongs to (by Net Assets): VTI, PINK, VXF, DFAT, AVSC.
LPTX has underperformed the market in the last year with a price return of -10.7% while the SPY ETF gained +24.2%. However, in the short term, LPTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +15.4% vs +4.6% return in SPY. But in the last 2 weeks, LPTX shares have been beat by the market, returning -3.5% compared to an SPY return of -2.7%.
LPTX support price is $2.94 and resistance is $3.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LPTX stock will trade within this expected range on the day.